Telmisartan as a metabolic sartan for targeting vascular failure

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 8, 2008, Pages 1397-1406

  Inoue, Tenuo ^a   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Cholesterol; Insulin resistance; Metabolic syndrome; PPAR ; Telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CHOLESTEROL; CLOPIDOGREL; DIPYRIDAMOLE; EPROSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; VALSARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; GLUCOSE METABOLISM; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; REVIEW; ARTICLE; BLOOD; BLOOD PRESSURE; DRUG EFFECT; METABOLISM; RISK FACTOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; GLUCOSE; HUMANS; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; PPAR GAMMA; RISK FACTORS;

EID: 45549108620     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.8.1397     Document Type: Review

References (59)

1. Siragy HM, Bedigian M. Mechanism of action of angiotensin-receptor blocking agent. Curr Hypertens Rep 1999;1(4):289-95
2. Siragy HM. AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000;36(3 Suppl 1):S4-9
3. Weir MR, Dzau VJ. The rennin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999;12(12 Pt 3):205S-213S
4. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002;113(5):409-18
5. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005;18(5 Pt 1):720-30
6. Wienen W, Entzeroth M, van Meel JC, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000;18(2):127-56
7. Sharpe M, Jarvis B. Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61(l0):1501-29
8. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004;43(5):993-1002
9. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-gamma activity. Circulation 2004; 109(17):2054-7
10. Yamauchi T, Kamon J, Waki Y, et al. The fat-derived hormone adiponectin reserves insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7(8):941-6
11. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARγ-activating angiotensin type-I receptor blockers induce adiponectin. Hypertension 2005;46:137-43
12. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care 2005;28(3):757-8
13. Kurtz TW, Pravenec M. Antidiabetic mechanisms of ACE inhibitors and AII receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004;22(12):2253-61
14. Stangier J, Schmid J, Turck D, et al. Absorption, metabolism, and excretion of intravenously and orally administrated [14C] telmisartan in healthy volunteers. J Clin Pharmacol 2000;40(12 Pt 1):1312-22
15. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003
16. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized doubleblind intervention trial. J Hypertens 2003;21(5):875-86
17. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363(9426):2002-31
18. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-6
19. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349(9054):747-52
20. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40(8):1414-21
21. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360(9335):752-60
22. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906
23. Kjeldsen SE, Dahlof B, Devereux RB, et al. Comparison of the SCOPE and LIFE results. J Hypertens 2003;21(9):1772-3
24. Diener HC, Sacco R, Yusuf S, et al. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23(5-6):368-80
25. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol 2003;91(10A):28-34
26. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89(2A):18A-25A
27. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163(13):1555-65.
28. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30(6):1577-8
29. Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004;44(4):406-13
30. Nakamura T, Inoue T, Suzuki T, et al. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res In press
31. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure the CHARM-Overall programme. Lancet 2003;362(9368):759-66
32. Velloso LA, Folli F, Sun XJ, et al. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996;93(22):12490-5
33. Folli, F Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest 1997;100(9):2158-69
34. Folli F, Saad MJA, Velloso L, et al. Crosstalk between insulin and angiotensin II signaling system. Exp Clin Endocrinol Diabetes 1999;107(2):133-9
35. Shiuchi T, Iwai M, Li H, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004;43(5):1003-10
36. Janke J, Schupp M, Engeli S, et al. Angiotensin type 1 receptor antagonists induce human in vitro adipogenesis through peroxisome proliferators-activated receptor-γ activation. J Hypertens 2006;24:1809-16
37. Erbe DV, Gartrell K, Zhang Y-L, et al. Molecular activation of PPAR-γ by angiotenin II type 1-receptor antagonists. Vasc Pharmacol 2006;45:154-62
38. Pershadsingh HA. Peroxisome proliferator-activated receptor-γ therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Invest Drugs 2004;13(3):215-28
39. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 2003;52(4):910-7
40. Diamant M, Heine RJ. TZDs in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63(13):1373-405
41. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14(Suppl 1):S73-86
42. Zhang H, Zhang A, Kohan DE, et al. Collecting duct-specific deletion of peroxisome proliferators-activated receptor g blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005;102:9406-11
43. Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89(3):1140-5
44. Michel MC, Bohner H, Köster J, et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004;27(5):335-44
45. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6-13
46. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism, and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Hypertens Res 2004;27(7):457-64
47. Inoue T, Morooka T, Moroe K, et al. Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007;39(5):372-6
48. Lee C, Olson P, Evans RM. Minireview: lipid metabolism, metabolic disease, and peroxisome proliferator-activated receptors. Endocrinology 2003;144(6):2201-7
49. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000;38(1):3-11
50. Von Eckardstein A, Nofer J, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21(1):13-27
51. Hoekstra M, Kruijt JK, van Eck M, van Berkel TJC. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem 2003;278(28):25448-53
52. Schupp M, Clemens M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensine receptor blocking activity. Diabetes 2005; 54(12):3442-52
53. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289(5484):24-9
54. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjuscent ABC transporters. Science 2000;290(5497):1771-5
55. Francis GA, Annicotte J, Auwerx J. Liver X receptors: Xcreting Xol to combat atherosclerosis. Trends Mol Med 2002;8(10):455-8
56. Clemenz M, Frost N, Schupp M, et al. Liver-specific PPAR-α target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008; [Epub ahead of print]
57. Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2007;20(4):431-6
58. Araki K, Masaki T, Karsuragi I, et al. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006;48(1):1-7
59. Inoue T, Node K. Vascular failure - a new clinical entity for vascular disease. J Hypertens 2006;24(11):2121-30